

We Claim:

1. A method for ameliorating tissue damage related to vascular leakage or edema comprising contacting said tissue with a vascular permeability modulating amount of a pharmaceutical composition comprising a Src family tyrosine kinase inhibitor.

2. The method of claim 1 wherein said Src family tyrosine kinase inhibitor is a chemical inhibitor.

3. The method of claim 2 wherein said chemical inhibitor is selected from the group consisting of PP1, PP2, PD173955, AGL1872, PD162531, Radicicol R2146, and Geldanamycin.

4. The method of claim 3 wherein said inhibitor is PP1.

5. The method of claim 1 wherein said Src family tyrosine kinase inhibitor is an inactive Src protein.

6. The method of claim 5 wherein said inactive Src protein is Src K295M.

7. The method of claim 5 wherein said inactive Src protein is Src 251.

8. The method of claim 1 wherein said Src family tyrosine kinase inhibitor is an inactive Yes protein.

9. The method of claim 1 wherein said Src family tyrosine kinase inhibitor is active c-terminal Src Kinase (CSK) protein.

10. A method of claim 1 wherein said Src family tyrosine kinase inhibitor is a nucleic acid encoding for a Src family tyrosine kinase inhibitor protein.

11. The method of claim 10 wherein said pharmaceutical composition includes a retroviral expression vector.

12. The method of claim 10 wherein said pharmaceutical composition includes a non-viral expression vector.

13. A method of claim 10 wherein said inhibitor protein is selected from the group consisting of inactive Src protein, inactive Yes protein, active c-terminal Src kinase (CSK), and a mixture thereof.

14. The method of claim 13 wherein said inactive Src protein is Src K295M.

15. The method of claim 13 wherein said inactive Src protein is Src 251.

16. A method of claim 1 wherein said inhibitor is a Src tyrosine kinase inhibitor.

17. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating vascular permeability increase in a tissue suffering from a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treatment of vascular leakage or edema associated disease conditions, and wherein said pharmaceutical composition comprises a Src family tyrosine kinase inhibitor and a pharmaceutically acceptable carrier therefor.

18. An article of manufacture of claim 17 wherein said Src family tyrosine kinase inhibitor is a chemical inhibitor.

19. An article of manufacture of claim 18 wherein said Src family tyrosine kinase inhibitor is selected from the group consisting of PP1, PP2, PD173955, AGL1872, PD162531, Radicicol R2146, and Geldanamycin.

Get  
20. An article of manufacture of claim 18 wherein said Src family tyrosine kinase inhibitor is PP1.

21. An article of manufacture of claim 17 wherein said Src family tyrosine kinase inhibitor is inactive Src protein.

5 22. An article of manufacture of claim 21 wherein said inactive Src protein is Src K295M.

23. An article of manufacture of claim 21 wherein said inactive Src protein is Src 251.

10 24. An article of manufacture of claim 17 wherein said Src family tyrosine kinase inhibitor is inactive Yes protein.

25. An article of manufacture of claim 17 wherein said Src family tyrosine kinase inhibitor is active c-terminal Src Kinase (CSK) protein.

15 26. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating vascular permeability in a tissue suffering from a disease condition, wherein said packaging material comprises a label which indicates that said  
20 pharmaceutical composition can be used for treatment of vascular leakage or edema associated disease conditions, and wherein said pharmaceutical composition comprises nucleic acid encoding for a Src family tyrosine kinase inhibitor, in a pharmaceutically acceptable carrier.

25 27. An article of manufacture of claim 26 wherein said Src family tyrosine kinase inhibitor is inactive Src protein.

28. An article of manufacture of claim 27 wherein said inactive Src protein is Src K295M.

30 29. An article of manufacture of claim 27 wherein said inactive Src protein is Src 251.

TSRI 651.3

- 95 -

30. An article of manufacture of claim 26 wherein said Src family tyrosine kinase inhibitor is inactive Yes protein.

31. An article of manufacture of claim 26 wherein said Src family tyrosine kinase inhibitor is active c-terminal Src

5 Kinase (CSK) protein.